Here is a summary of our coverage from ASCO20 Virtual, the annual meeting for the American Society of Clinical Oncology (ASCO).
Transcript
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
The American Society of Clinical Oncology held its annual meeting, ASCO20 Virtual, from May 29 through May 31. The meeting was conducted on a digital platform because of the coronavirus disease 2019 (COVID-19) pandemic and featured a number of study findings and presentations on the importance and potential impact of oncology biosimilars.
The following is a summary of our biosimilar coverage from this event:
A study presented during the conference demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.
Prestige BioPharma of Singapore has successful clinical trials to support its bid to market a trastuzumab biosimilar candidate (HD201, Tuznue), based on findings presented at ASCO20 Virtual.
A study presented during the conference revealed that oncologists are less likely to prescribe biosimilars if there is potential for their practices to lose money or control over the preferred medication.
Another study showed very high recognition and knowledge of biosimilars among oncologists in Brazil, where biosimilars could make a difference, and noted utilization barriers that could be overcome with education.
The idea that “resources affect who lives and dies” is cringeworthy, but this is a very real phenomenon that reveals itself in multiple ways throughout the US cancer treatment system, said Devika Das, MBBS, who reviewed the evidence presented at ASCO20 Virtual, and concluded that some deep reforms are needed in oncology care to improve access.
Cancer drug prices are rising in the United States and Europe, however European regulators allow for negotiating of drug prices unlike the US, and the results are seen in pricing trends, investigators said in a conference presentation.
A study revealed that the rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity and was similar to that of the reference product (Rituxan in the United States and MabThera in the European Union).
When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non—small cell lung cancer (NSCLC), according to a study presented at the conference.
Investigators found that switching patients with cancer from reference pegfilgrastim (Neulasta) to biosimilar pegfilgrastim (Udenyca) not only reduces the cost of prophylaxis treatment for chemotherapy-induced febrile neutropenia (FN) but also provides funds for adjuvant treatment.
A real-world study of patients with breast cancer who received febrile neutropenia prophylaxis with biosimilar pegfilgrastim (Udenyca) or reference pegfilgrastim (Neulasta) has not only demonstrated comparable efficacy between the 2 products but also shown that large-scale comparisons of this nature can be done.
To read all of these articles and more visit centerforbiosimilars.com.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.